– FRANCE, Marseille – Vect-Horus, a biotech company that designs and develops vectors that enable therapeutic molecules or imaging agents to be delivered to key organs, today announced the completion of its Series D funding round, bringing the total amount raised in these two rounds to €12 million.
The first round, held in September 2020, raised €6.7 million and a second-round in December 2020 added €5.3 million from private investors,
This second funding round strengthens the company’s capital so it can pursue its ambitious programs, focusing on identifying new vectors, developing theragnostic agents in a clinical setting, and validating its technology for delivering therapeutic antibodies and nucleic acids.
The health crisis has for the first time highlighted the enormous therapeutic potential of messenger RNAs encapsulated in lipid nanoparticles. These mRNAs are used to express proteins of interest in the body. In contrast, antisense oligonucleotides or small interfering RNAs inhibit the expression of a particular gene and therefore the corresponding protein.
Using the company’s VECTrans platform, nanoparticles of mRNA, as well as ASOs and siRNAs, can be vectorized to treat both diseases with a genetic component and cancers.
‘Very promising in vivo results have been obtained, for example on skeletal muscle. This means that there is a great potential for our technology to transport nucleic acids and to treat muscular pathologies,’ said Board Chairman, Alexandre Tokay.
VECT-HORUS designs and develops vectors that facilitate the targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. VECT-HORUS combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, VECT-HORUS is a spin-off of the Institute for Neurophysiopathology, headed by Dr. Michel Khrestchatisky, the co-founder.
For more information: https://www.vect-horus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.